Cargando…
Proteomics-Driven Biomarkers in Pancreatic Cancer
Pancreatic cancer is a devastating disease that has a grim prognosis, highlighting the need for improved screening, diagnosis, and treatment strategies. Currently, the sole biomarker for pancreatic ductal adenocarcinoma (PDAC) authorized by the U.S. Food and Drug Administration is CA 19-9, which pro...
Autores principales: | Ramalhete, Luís, Vigia, Emanuel, Araújo, Rúben, Marques, Hugo Pinto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443269/ https://www.ncbi.nlm.nih.gov/pubmed/37606420 http://dx.doi.org/10.3390/proteomes11030024 |
Ejemplares similares
-
Proteomics for Biomarker Discovery for Diagnosis and Prognosis of Kidney Transplantation Rejection
por: Ramalhete, Luís M., et al.
Publicado: (2022) -
Delayed presentation of isolated grade III pancreatic injury—a case report
por: Ferreira, Maria João, et al.
Publicado: (2023) -
Pancreas Rejection in the Artificial Intelligence Era: New Tool for Signal Patients at Risk
por: Vigia, Emanuel, et al.
Publicado: (2023) -
Aquaporins Transcripts with Potential Prognostic Value in Pancreatic Cancer
por: Lopes, Paula A., et al.
Publicado: (2023) -
Two-stage pancreatic head resection after previous damage control surgery in trauma: two rare case reports
por: Paulino, Jorge, et al.
Publicado: (2020)